Vega Juan Carlos, Sanchez Boris Fernando, Montero Luz Mery, Montaña Rafael, Del Pilar Mahecha Mercedes, Dueñes Bladimir, Baron Angela Rocío, Reithinger Richard
Universidad Militar Nueva Granada, Santafé de Bogotá, Colombia, and Universidad del Bosque, Bogotá, Colombia.
Trop Med Int Health. 2007 Dec;12(12):1540-4. doi: 10.1111/j.1365-3156.2007.01962.x.
We calculated ranges for the cost per disability adjusted life year (DALY) averted for cutaneous leishmaniasis (CL) treatment during an ongoing epidemic of CL in Chaparral, Colombia. Using operational clinical and cost data, we calculated that the cost of treating leishmaniasis patients with standard pentavalent antimony was US$345 (95% CI 277-488) per patient treated and cured. The cost per DALY averted per patient cured with antimony was estimated to be approximately US$15 000 (95% CI 12 226-21 532).
BMC Public Health. 2018-1-29
Am J Trop Med Hyg. 2005-4
Int J Antimicrob Agents. 2005-1
Rev Med Suisse Romande. 1989-6
PLoS One. 2016-6-3
Med J Islam Repub Iran. 2024-10-30
Rev Inst Med Trop Sao Paulo. 2021
Infect Dis Poverty. 2018-2-14
BMC Public Health. 2018-1-29
Braz J Otorhinolaryngol. 2015
Zotero 插件